WSI, Exclusive Domestic Supplier of Chinese Shengkentec's 'Cardiovascular Medical Devices'

WSI announced on the 20th that it has signed an exclusive domestic supply contract for cardiovascular medical devices with Lifetech Scientific (Korean name: Seongeontekeo) Group, a leading Chinese company in heart disease medical devices.

Through this contract, WSI plans to exclusively distribute the heart disease treatment devices ‘KONAR-MF™’ and ‘ANKURA™’ in South Korea. This will enable the company to target the domestic cardiovascular disease market, which is expanding due to an aging population.

KONAR-MF is a medical device used to treat ventricular septal defects. Unlike existing products that could only treat membranous septal defects, it can also treat muscular septal defects and defects occurring beneath the great vessels. ANKURA is a stent graft for thoracic and abdominal aortic aneurysm interventions. It can treat aneurysms occurring in the arteries leading to the kidneys, making it useful in emergency situations. It is already widely used in advanced medical countries such as the United States and Europe.

Lifetech Scientific is a global medical device company holding the number one market share in Europe for structural heart disease-related fields. It manufactures and sells devices for congenital and structural heart diseases, peripheral vascular diseases, and surgical vascular treatments in over 100 countries worldwide.

Previously, in October last year, WSI signed a strategic business agreement (MOU) with Lifetech Scientific to establish new growth engines. The two companies agreed to expand their cardiovascular interventional medical device business and to collaborate on joint research and clinical trials for products under development. Comprehensive business cooperation is also underway for the obstetrics and gynecology laparoscopic surgery robot ‘U-Bot,’ developed by WSI’s subsidiary Easy Medibot.

A WSI representative stated, "By expanding our portfolio of cardiovascular interventional procedure-related products, we have secured strong business competitiveness in the domestic cardiovascular market, which has been monopolized by global medical device companies. Moving forward, we will strengthen cooperation with global companies to establish ourselves as an emerging leader in the cardiovascular interventional procedure market and secure new growth engines for the company."